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Abstract
Introduction: Little research has examined whether cardiovascular medications, other than statins, are associated with
improved outcomes after pneumonia. Our aim was to examine the association between the use of beta-blockers, statins,
angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) with pneumonia-related
outcomes.
Materials and Methods: We conducted a retrospective population-based study on male patients $65 years of age
hospitalized with pneumonia and who did not have pre-existing cardiac disease. Our primary analyses were multilevel
regression models that examined the association between cardiovascular medication classes and either mortality or
cardiovascular events.
Results: Our cohort included 21,985 patients: 22% died within 90 days of admission, and 22% had a cardiac event within 90
days. The cardiovascular medications studied that were associated with decreased 90-day mortality included: statins (OR
0.70, 95% CI 0.63–0.77), ACE inhibitors (OR 0.82, 95% CI 0.74–0.91), and ARBs (OR 0.58, 95% CI 0.44–0.77). However, none of
the medications were significantly associated with decreased cardiovascular events.
Discussion: While statins, ACE inhibitors, and ARBs, were associated with decreased mortality, there was no significant
association with decreased CV events. These results indicate that this decreased mortality is unlikely due to their potential
cardioprotective effects.
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Introduction
Pneumonia affects 4 million people annually and is the eighth
leading cause of death in the United States [1]. In 2007, in the
United States there were 1.1 million hospitalizations due to
pneumonia [2]. The number of patients admitted to hospitals for
pneumonia is increasing, which may be due to an increase in an
aging population as well as an increase in the number of co-
morbid conditions [3].
Several studies have indicated that pneumonia may be
associated with increased risk of heart disease, the leading cause
of death in the United States [4–6]. These studies suggest that
patients with concurrent pneumonia and cardiac events have
significantly higher mortality than patients who only had
pneumonia [4,7]. Recent studies have shown that the use of
statins and/or angiotensin-converting enzyme (ACE) inhibitors
prior to admission is associated with decreased mortality in
patients hospitalized with pneumonia [8–10]. It is unclear,
however, whether this is due to cardioprotective effects or non-
cardiovascular beneficial effects of these medications. In addition,
while research has linked pneumonia and cardiovascular events, it
is unclear whether use of cardioprotective medications, other than
statins, are associated with improved clinical outcomes, such as
mortality or cardiac events, for patients with pneumonia.
The aim of our study was to examine the association between
the use of cardioprotective medications (e.g., beta-blockers, statins,
ACE inhibitors, and ARBs) and 90-day mortality, and hospital
admission due to cardiovascular events within 90-days, for male
patients $65 years of age hospitalized with pneumonia using the
extensive data of the Department of Veterans Affairs administra-
tive databases. We hypothesized that in patients hospitalized with
pneumonia, use of these cardiovascular medications would be
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associated with lower 90-day mortality and fewer cardiovascular
events within 90-day of hospitalization.
Materials and Methods
For this retrospective population-based study we used the
administrative databases of the Department of Veterans Affairs
(VA) Health Care System. These databases are the repositories of
clinical data from all of the VA hospitals and outpatient clinics
[11]. The Institutional Review Boards of the University of Texas
Health Science Center at San Antonio and VA North Texas
Health Care System approved this study. A waiver of informed
consent was obtained from both ethics boards, as this was a
retrospective study.
Inclusion/Exclusion Criteria
Subjects included in this study met all of the following criteria:
a) Age 65 or older on the date of admission.
b) Had at least one outpatient clinic visit in the year preceding
the index admission.
c) Received at least one active and filled outpatient medication
within 90-days of admission.
d) Were hospitalized during fiscal years 2002–2007 (Oct 2001–
Sep 2007) with a validated discharge diagnosis of pneumo-
nia/influenza- either a primary ICD-9 codes 480.0–483.99 or
485–487 [12] or a secondary discharge diagnosis of
pneumonia with a primary diagnosis of respiratory failure
(ICD-9 code 518.81) or sepsis (ICD-9 code 038.xx) [12].
e) Received at least one dose of antimicrobial therapy within the
first 48 hours of admission.
f) Did not have a pre-existing history of cardiac disease as
defined previously [5]. We excluded those with a prior history
of coronary artery disease, congestive heart failure, and/or
arrhythmias as for subjects with these cardiac conditions we
were unable to determine if a subsequent diagnosis was due
to a new cardiac event or that the treating physicians felt that
the pre-existing cardiac disease complicated the hospital stay.
We excluded women due to the small number who meet the
inclusion criteria (n = 438). If a subject was admitted more than
once for pneumonia during the study period, only the first
hospitalization was included.
Data
We used demographic, utilization, and comorbidity data from
the National Patient Care Database, pharmacy data from the VA
Decision Support System National Data Extracts (DSS NDE) and
Pharmacy Benefits Management (PBM), and vital status informa-
tion from VA’s Vital Status file, which incorporates data from
veterans’ death benefits claims, inpatient deaths, Medicare Vital
Status files, and the Social Security Administration death master
file. Encrypted patient identifiers linked the information across
these databases.
We obtained demographic information (age, sex, race, marital
status) from inpatient and outpatient data. Race categories
included white, black, Hispanic, and other/unknown. To infer
active smoking and/or tobacco cessation attempts, we identified
ICD-9 codes for tobacco use (305.1, V15.82), smoking cessation
clinic use, and/or use of medications for the treatment of nicotine
dependence (Zyban, nicotine replacement, or varenicline). Priority
groups include (a) at least 50% disabled by a military service-
connected condition (priority group 1), (b) up to 40% service-
connected disability or special wartime cohorts such as recent
Table 1. Demographic and Clinical Characteristics of Patients
Hospitalized with Pneumonia (N = 21,985).
Variables N (%)
Demographics






ICU admission 2,791 (12.7)
Vasopressor Use 911 (4.1)
Mechanical ventilation 1,377 (6.3)
VA Priority group 1 3,744 (17.1)
VA Priority group 2–6 16,177 (73.7)
VA Priority group 7–8 2,036 (9.3)
Comorbid conditions
Tobacco use/cessation 8,388 (38.2)
Alcohol abuse 1,092 (4.9)
Drug abuse 244 (1.1)
Peripheral vascular disease 2,536 (11.5)
Chronic obstructive pulmonary disease 10,628 (48.3)




Diabetes with complication 1,478 (6.7)
Liver disease 92 (0.4)
Paraplegia 350 (1.6)
Renal disease 1,698 (7.7)
Cancer 5,479 (24.9)
Cancer with metastasis 924 (4.2)
AIDS 69 (0.3)
Charlson score, mean (SD) 2.3 (2.2)
Medications
Pulmonary medications, mean (SD) 1.2 (1.9)
Diabetes medications, mean (SD) 0.3 (0.6)
Cardiac medications, mean (SD) 1.2 (1.4)
Corticosteroids, mean (SD) 0.3 (0.7)
Beta-blockers 4,855 (22.1)
Statins 5,301 (24.1)
ACE inhibitors 4,121 (19.7)
ARBs 535 (2.5)
Outcomes
90-day mortality 4,873 (22.2)
Any cardiovascular event within 90 days 4,808 (21.9)
Myocardial Infarction within 90 days 1,009 (4.6)
CHF within 90 days 3,862 (17.6)
Arrhythmia within 90 days 3,984 (18.1)
doi:10.1371/journal.pone.0085797.t001
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Afghanistan or Iraqi veterans (priority groups 2–6), and (c) higher
income patients with no service connected injuries (priority groups
7–8). We used VA priority status as a proxy for socioeconomic
status.
We also obtained information on comorbid conditions from
inpatient and outpatient administrative data. Alcohol abuse was
defined by ICD-9 codes 291, 303, 305.0, and illicit drug use by
ICD-9 codes 292, 304, 305 excluding 305.0-.1. We used the
Charlson comorbidity index to quantify levels of preexisting
comorbidity [13], adapted for administrative databases, using
ICD-9 codes for 19 comorbid conditions from prior outpatient
and inpatient encounters.
Pharmacy data were obtained from the PBM databases as well
as from the DSS NDEs. Subjects were considered a current user of
a given medication if they had enough pills to last until the date of
hospitalization assuming an 80% compliance rate. To further
adjust for potential confounding, a count of unique drugs in each
of the following classes per patient was calculated for drugs
prescribed within 90-days of presentation: other cardiac (excluding
statins, ACE inhibitors, ARBs, and beta-blockers), pulmonary and
diabetic medications. In addition, a dichotomized variable was
created to identify those with intravenous or oral corticosteroid use
within 90-days prior to hospitalization.
We also assessed for intensive care unit admission, receipt of
invasive mechanical ventilation, and/or need for vasopressors, all
within 48 hours of the index admission.
Definition of exposure
Medications were classified as: statins (atorvastatin, cerivastatin,
fluvastatin, lovastatin, pravastatin, and simvastatin); ACE inhibi-
tors (benazepril, captopril, enalapril, fosinopril, lisinopril, moex-
ipril, quinapril, and ramipril); ARBs (candesartan, irbesartan,
valsartan, losartan, telmisartan, eprosartan, and olmesartan); or
beta-blockers (metoprolol, atenolol, carvedilol, propranolol, biso-
prolol, labetalol, nadolol, pindolol, and timolol). We created
dichotomous variables to identify use of statins, ACE inhibitors,
ARBs, or beta-blockers, which we defined as a filled prescription
for the medication of interest within 90-days of presentation, with
a sufficient supply to overlap the date of admission, assuming 80%
compliance.
Outcomes
Our primary outcomes were 90-day all-cause mortality or any
cardiovascular event (e.g. myocardial infarction, congestive heart
failure, and/or cardiac arrhythmia) within 90 days after admission.
New cardiac events were identified after the date of admission
using inpatient ICD-9 criteria [5]. Mortality was determined using
the VA Vital Status File, which has been demonstrated to be as
accurate as the ‘‘gold standard’’ National Death Index.
Statistical Analyses
Bivariate statistics were used to test the association of socio-
demographic and clinical characteristics with outcomes of 90-day
mortality or cardiovascular events within 90-days. Categorical
variables were analyzed using the chi-square test and continuous
Figure 1. Mortality within 90-days by Prior Cardiovascular Medications Received (all p,0.001).
doi:10.1371/journal.pone.0085797.g001
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variables were analyzed using Student’s t-test. To analyze time to
mortality or cardiovascular events for patients by cardiovascular
medications, we used a Kaplan-Meier graph to display the failure
functions. Statistical significance was assessed using the log-rank
test.
Next we created two generalized linear mixed-effect regression
models (‘‘multi-level model’’) to examine the association of the
cardiovascular medications on either 90-day mortality or cardio-
vascular events within 90-days with the patient’s hospital as a
random effect. Other factors included in the models included
demographics, intensive care unit admission, need for mechanical
ventilation and/or vasopressors, prior comorbid conditions, and
other outpatient medications.
Comparisons were considered statistically significant for two-
tailed p-values#0.05. All analyses were performed using STATA
13 (StataCorp LP, College Station, Texas).
Results
The cohort included 21,985 patients with a mean age of 74.6
years and 52% were married (Table 1). Whites comprised 80% of
the cohort, 13% were black and 7% were of Hispanic ethnicity. In
this cohort the most common comorbid conditions were chronic
obstructive pulmonary disease (COPD) 48%, uncomplicated
diabetes 26%, non-metastatic cancer 25% and peripheral vascular
disease 12%. Mortality at 90 days was 22%, and 22% had a new
cardiac event within 90 days of hospitalization.
Figure 1 demonstrates time to death over time by prior
cardiovascular medication use. Patients who had prior use of
statins, beta-blockers, ARBs, and ACE inhibitors, all had
significantly lower rates of mortality as compared to non-users
(all p-values,0.0001.) Figure 2 demonstrates time to event for new
cardiovascular events over time by prior cardiovascular medica-
tion use. Patients who received ACE inhibitors had significantly
lower rates of new cardiovascular events as compared to non-users
(p = 0.03.) There was no significant association between statin,
ARB, or beta-blocker use (all p-values.0.5) and cardiovascular
events.
To examine the impact of the medications of interest on our
outcomes we performed two multilevel regression analyses. The
first examined the impact of these medications on 90-day mortality
after adjusting for other potential confounders (Table 2). Cardiac
medications associated with decreased 90-day mortality included
statins (OR 0.70, 95% CI 0.63–0.77), ACE inhibitors (OR 0.82,
95% CI 0.74–0.91), and ARBs (OR 0.58, 95% CI 0.44–0.77).
Beta- blockers (OR 0.98, 95% CI 0.89–1.09) had no significant
association with 90-day mortality. For the outcome of any cardiac
event within 90-days none of the potential protective medications
were significantly associated with decreased events (Table 3).
Discussion
Patients hospitalized for pneumonia are at high risk for
cardiovascular events within 90 days of hospitalization [5,14,15]
Figure 2. Percentage of the Cohort With Incident Cardiovascular Events by Prior Cardiovascular Medication Use (only significant
association was with ACE inhibitors p=0.03).
doi:10.1371/journal.pone.0085797.g002
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and patients with concurrent pneumonia and cardiac events have
significantly higher mortality than patients who only had
pneumonia [16]. Our study sought to examine whether cardio-
protective medications are associated with both lower mortality
and cardiovascular events in order to better define if the previously
demonstrated lower pneumonia-related mortality associated with
these medication are due to cardioprotective effects. While we
found that statins, ACE inhibitors, and ARBs were associated with
lower mortality, there was no significant association between these
medications and lower cardiovascular events. Thus, our data
suggests that beneficial effects of statin, ACE inhibitors, and ARBs
on mortality in patients admitted with pneumonia may not be due
to prevention of future cardiac events, but other mechanisms.
There is considerable literature demonstrating a significant
number of cardiac events in patients with pneumonia [4–6,14,15].
One possible explanation is that an acute increase in inflammatory
cytokines [17,18] leads to instability of previously established
atherosclerotic plaques [19]. Another possible mechanisms include
mismatches between oxygen supply and demand may also cause
increased cardiovascular events for patients with pneumonia [4,6].
Finally, many of the bacteria that cause pneumonia have
demonstrated the ability to directly infect cardiomyocytes, and
cause conduction and contractility dysfunction [20–23]. For
example, the most common cause of community-acquired
pneumonia, Streptococcus pneumoniae, has recently been implicated
in causing decreased cardiac contractility through immune-
mediated uptake of bacterial cell wall antigen into cardiomyocytes
[24].
There are several potential reasons that these medications may
be protective against pneumonia-related mortality besides the
demonstrated cardioprotective effects of statins, ACE inhibitors,
and ARBs [10]. Both statins and ACE inhibitors have been
Table 2. Results of Multivariable Regression of Model for
Outcome of 90-day Mortality.
Variable Odds Ratio 95% CI P-Value
Beta Blockers 0.98 0.89–1.09 0.96
Statins 0.70 0.63–0.77 ,0.001
ACE inhibitors 0.82 0.74–0.90 ,0.001
ARBs 0.58 0.44–0.77 ,0.001
Age at admission 1.04 1.04, 1.05 ,0.001
Black 0.98 0.88–1.09 0.72
Hispanic 0.84 0.71–1.04 0.12
Married 0.96 0.89–1.03 0.20
ICU 2.47 2.21–2.77 ,0.001
Vasopressor Use 2.89 2.42–3.46 ,0.001
Mechanical Ventilation 2.14 1.82–2.52 ,0.001
Priority groups 2–6 1.15 1.05–1.27 0.003
Priority groups 7–8 1.05 0.91–1.21 0.49
Smoking 0.77 0.71–0.84 ,0.001
Alcohol Abuse 0.92 0.78–1.10 0.29
Drug abuse 0.64 0.43–0.95 0.03
Peripheral vascular disease 1.18 1.06–1.32 0.002
Chronic obstructive pulmonary disease 0.98 0.89–1.06 0.56
Rheumatologic disease 0.97 0.77–1.20 0.77
Cirrhosis 1.74 1.20–2.55 0.004
Dementia 1.47 1.28–1.70 ,0.001
Diabetes 1.12 1.01–1.26 0.04
Diabetes with complication 0.97 0.8–1.13 0.67
Liver disease 1.56 0.91–2.68 0.11
Paraplegia 1.08 0.82–1.42 0.58
Renal disease 1.22 1.08–1.40 0.002
Cancer 1.63 1.50–1.77 ,0.001
Cancer with metastasis 3.49 3.00–3.10 ,0.001
AIDS 1.03 0.51–2.01 0.92
Other cardiac medications* 0.93 0.90–0.96 ,0.001
Pulmonary medications* 0.99 0.97–1.01 0.53
Diabetes medications* 0.93 0.96–1.01 0.09
Corticosteroids* 1.06 1.01–1.12 0.03
*Per each additional prescription.
doi:10.1371/journal.pone.0085797.t002
Table 3. Results of Multivariable Regression of Model for
Outcome of Incident Cardiovascular Event within 90 days.
Variable Odds Ratio 95% CI P-Value
Beta Blockers 1.01 0.93–1.13 0.64
Statins 1.10 0.99–1.20 0.06
ACE inhibitors 1.02 0.93–1.12 0.56
ARBs 1.013 0.82–1.28 0.81
Age at admission 1.03 1.03–1.04 ,0.001
Black 0.74 0.65–0.83 ,0.001
Hispanic 0.75 0.62–0.91 0.004
Married 0.93 0.87–1.0 0.051
ICU 3.11 2.78–3.50 ,0.001
Vasopressor Use 0.95 0.78–1.14 0.57
Mechanical Ventilation 1.10 0.93–1.30 0.25
Priority groups 2–6 0.96 0.87–1.05 0.003
Priority groups 7–8 1.04 0.91–1.20 0.49
Tobacco use/cessation 0.99 0.91–1.07 0.73
Alcohol abuse 0.98 0.82–1.16 0.78
Drug abuse 1.21 0.86–1.70 0.27
Peripheral vascular disease 1.09 0.98–1.21 0.11
Chronic obstructive pulmonary disease 0.99 0.91–1.08 0.85
Rheumatologic disease 1.07 0.86–1.33 0.52
Cirrhosis 0.99 0.64–1.53 0.97
Dementia 0.65 0.55–0.77 ,0.001
Diabetes 1.10 0.98–1.22 0.09
Diabetes with complication 1.02 0.87–1.19 0.82
Liver disease 0.93 0.49–1.74 0.81
Paraplegia 0.45 0.31–0.64 ,0.001
Renal disease 1.05 0.92–1.19 0.48
Cancer 0.86 0.79–0.94 0.001
Cancer with metastasis 0.72 0.58–0.94 0.003
AIDS 0.87 0.43–1.75 0.69
Other cardiac medications* 1.10 1.07–1.13 ,0.001
Pulmonary medications* 1.03 1.01–1.05 0.006
Diabetes medications* 1.04 0.96–1.12 0.32
Corticosteroids* 0.94 0.89–0.99 0.04
*Per each additional prescription.
doi:10.1371/journal.pone.0085797.t003
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demonstrated to blunt systemic inflammatory responses, which are
also triggered in pneumonia [25,26]. Statins also affect coagula-
tion, cellular apoptosis, inflammatory cell signaling, leukocyte-
endothelial cell adhesion, nitric oxide balance, and have anti-
bacterial effects [27]. ACE inhibitors have also been demonstrated
to have protective pulmonary effects [28], and two recent studies
demonstrated that a genetic polymorphism associated with
increased activity of the renin-angiotensin system is associated
with increased incidence of, or higher mortality from, acute
respiratory distress syndrome [29,30].
There were several limitations to this study. Due to the small
number of female patients available we were unable to examine if
similar results would be found for women. Also the VA population
is generally more medically complex and socioeconomically
deprived than the general population so it is unclear how
generalizable these results are [31]. We were also unable to
examine whether the cause of pneumonia (bacterial or viral)
influenced our results due to the study design. In addition, death
certificate cause of death information was not available however
prior studies have demonstrated that this information is frequently
unreliable [32,33]. Another limitation was reliance on ICD-9
diagnosis of cardiovascular events rather than clinical information,
which particularly may impact the diagnosis of congestive heart
failure. Not infrequently there is clinical confusion about whether
patients have congestive heart failure, pneumonia, or both. We are
unable to determine the extent to which these conditions may have
been improperly differentiated. However due to our definition of
pneumonia we are confident that the treating physicians believed
that pneumonia was present. Also, we did not have clinical data,
e.g., cardiac enzymes, B-type natriuretic peptide levels, radiogra-
phy and echocardiogram results, available to confirm the diagnosis
of cardiovascular events. Finally, we found it necessary to exclude
those with pre-existing cardiac diagnoses from the sample due to
difficulties in determining if subsequent discharge diagnoses
represent new events or complicating factors during the hospital-
ization.
In conclusion, cardiovascular medications such as statins, ACE
inhibitors, and ARBs, were associated with decreased mortality in
patients hospitalized with pneumonia but not cardiovascular
events. Additional research, especially prospective cohort and
randomized trials, are needed to further examine the potential
mechanism(s) of these associations and to determine if starting
these medications at the time of diagnosis may be beneficial. For
patients who are already taking these medications they should be
continued unless there is direct contraindication (e.g., hypotension
in a patient on ACE inhibitor or ARB).
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